MedTrace Logo

GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans

NCT02731664 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-08-09

No results posted yet for this study

Summary

The inhibitory effect of low dose GLP-1 is investigated on prandial motility of the stomach, duodenum and jejunum in vivo in humans. Supplementary in vitro studies on the mechanism of action of the GLP-1 inhibition of motility as carried out on muscle strips from the upper gastrointestinal tract in man.

Conditions

  • Functional Gastrointestinal Disorders

Interventions

BIOLOGICAL

GLP-1

Intravenous infusion of GLP-1

BIOLOGICAL

Intravenous saline

Control

Sponsors & Collaborators

Principal Investigators

  • Per M. Hellström, MD, PhD · Uppsala University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02731664 on ClinicalTrials.gov